BioVie Inc. BIVI

Full chart Compare

Set alert

1.73 USD +0.36 (+26.28%)

At closeNov 4, 2026, 4:18 AM EST

1.70 -0.03 -1.73%

Pre-market · Nov 4, 4:18 AM ET

1.40 Day range 2.66

0.82 52-week range 3.79

YTD: +49.14%
1 year: +1.17%

News

16 hours ago benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Curis (NASDAQ:CRIS) stock increased by 25.6% to $0.83 during Tuesday's regular session. The company's market cap stands at $1.6 million. Pasithea Therapeutics (NASDAQ:KTTA) shares increased…
1 day ago benzinga.com BioVie Invited To Present Late-Breaking Oral Presentation At The 4th Long Covid International Conference, November 12-13 Dr. Penelope Markham, BioVie’s Senior Vice President and Program Lead for Long COVID, will share the presentation titled "Bezisterim Improves Fatigue, Post-Exertional Malaise, and Cognition in…
1 day ago globenewswire.com BioVie Selected for Late-Breaking Oral Presentation of Bezisterim Long COVID Data at the 4th Long COVID International Conference 2026 CARSON CITY, Nev., Nov. 02, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and…
1 day ago defenseworld.net BioVie Inc. (NASDAQ:BIVI) Shares Shorted: Short Interest Down 34.5% in October BioVie Inc. (NASDAQ: BIVI - Get Free Report) was the recipient of a large decline in short interest during the month of October. As of October 15th, there was short interest totaling 544,444 shares,…
2 weeks ago benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers SCWorx (NASDAQ:WORX) stock moved upwards by 42.9% to $3.83 during Tuesday's regular session. Myriad Genetics (NASDAQ:MYGN) shares moved upwards by 36.85% to $5.76. The company's market cap…
2 weeks ago benzinga.com BioVie Reports Data From Phase 2 ADDRESS-LC Trial Of Bezisterim At 151st Annual Meeting Of American Neurological Association BioVie Inc. (NASDAQ: BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the presentation…